ION582 clinical trials

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

This study, called HALOS, is looking at a new medicine called ION582 for Angelman syndrome. It aims to see if different doses are safe, how the body handles the medicine, and how it affects the condition. It includes children and adults up to 50 years old.